- Home
- KRON vs ICCC Comparison
KRON vs ICCC Comparison
Compare KRON & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ICCC
- Stock Information
- Founded
- KRON 2017
- ICCC 1982
- Country
- KRON United States
- ICCC United States
- Employees
- KRON 8
- ICCC N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- ICCC Health Care
- Exchange
- KRON Nasdaq
- ICCC Nasdaq
- Market Cap
- KRON 54.1M
- ICCC 60.1M
- IPO Year
- KRON 2020
- ICCC 1987
- Fundamental
- Price
- KRON $0.88
- ICCC $6.62
- Analyst Decision
- KRON Buy
- ICCC
- Analyst Count
- KRON 3
- ICCC 0
- Target Price
- KRON $1.63
- ICCC N/A
- AVG Volume (30 Days)
- KRON 1.4M
- ICCC 42.4K
- Earning Date
- KRON 08-07-2025
- ICCC 08-12-2025
- Dividend Yield
- KRON N/A
- ICCC N/A
- EPS Growth
- KRON N/A
- ICCC N/A
- EPS
- KRON N/A
- ICCC N/A
- Revenue
- KRON $9,192,000.00
- ICCC $27,302,766.00
- Revenue This Year
- KRON N/A
- ICCC N/A
- Revenue Next Year
- KRON N/A
- ICCC N/A
- P/E Ratio
- KRON N/A
- ICCC N/A
- Revenue Growth
- KRON 21.16
- ICCC 28.29
- 52 Week Low
- KRON $0.65
- ICCC $3.34
- 52 Week High
- KRON $1.60
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- KRON 65.76
- ICCC 52.40
- Support Level
- KRON $0.87
- ICCC $5.63
- Resistance Level
- KRON $0.90
- ICCC $7.14
- Average True Range (ATR)
- KRON 0.01
- ICCC 0.60
- MACD
- KRON -0.00
- ICCC -0.02
- Stochastic Oscillator
- KRON 40.19
- ICCC 53.11
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.